NASDAQ:BTAIBioXcel Therapeutics Stock Price, Forecast & News

BioXcel Therapeutics' stock was trading at $29.48 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BTAI stock has increased by 60.5% and is now trading at $47.31. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BioXcel Therapeutics.

BioXcel Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for BioXcel Therapeutics.

BioXcel Therapeutics Inc (NASDAQ:BTAI) announced its quarterly earnings data on Tuesday, May, 12th. The company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.58) by $0.21. View BioXcel Therapeutics' earnings history.

5 equities research analysts have issued twelve-month target prices for BioXcel Therapeutics' stock. Their forecasts range from $24.00 to $95.00. On average, they anticipate BioXcel Therapeutics' share price to reach $59.80 in the next year. This suggests a possible upside of 26.4% from the stock's current price. View analysts' price targets for BioXcel Therapeutics.

Media coverage about BTAI stock has trended very positive recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. BioXcel Therapeutics earned a news sentiment score of 3.5 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutBioXcel Therapeutics.

BioXcel Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 852,400 shares, an increase of 30.0% from the April 30th total of 655,500 shares. Based on an average trading volume of 700,400 shares, the days-to-cover ratio is presently 1.2 days. Approximately 8.1% of the shares of the company are short sold. View BioXcel Therapeutics' Current Options Chain.

Some companies that are related to BioXcel Therapeutics include Biohaven Pharmaceutical (BHVN), Agios Pharmaceuticals (AGIO), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Arrowhead Pharmaceuticals (ARWR), Deciphera Pharmaceuticals (DCPH), Amicus Therapeutics (FOLD), PTC Therapeutics (PTCT), Allakos (ALLK), Arena Pharmaceuticals (ARNA), FibroGen (FGEN), Uniqure (QURE), HUTCHISON CHINA/S (HCM), Axsome Therapeutics (AXSM) and Amarin (AMRN). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include Alibaba Group (BABA), Crispr Therapeutics (CRSP), NVIDIA (NVDA), Inseego (INSG), Editas Medicine (EDIT), Micron Technology (MU), InVitae (NVTA), Tesla (TSLA), Square (SQ) and Cisco Systems (CSCO).

(BTAI) raised $60 million in an initial public offering on Thursday, March 8th 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets served as the underwriters for the IPO and Canaccord Genuity was co-manager.

BioXcel Therapeutics trades on the NASDAQ under the ticker symbol "BTAI."

BioXcel Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Artemis Investment Management LLP (3.90%), Artemis Investment Management LLP (3.90%), BlackRock Inc. (2.47%), Driehaus Capital Management LLC (1.49%), Massachusetts Financial Services Co. MA (1.36%) and Nuveen Asset Management LLC (0.76%). Company insiders that own BioXcel Therapeutics stock include Frank Yocca, Peter Mueller, Richard I Steinhart and Vimal Mehta. View institutional ownership trends for BioXcel Therapeutics.

BTAI stock was sold by a variety of institutional investors in the last quarter, including Artemis Investment Management LLP, Artemis Investment Management LLP, Squarepoint Ops LLC, Wells Fargo & Company MN, JPMorgan Chase & Co., UBS Group AG, Morgan Stanley, and Creative Planning. View insider buying and selling activity for BioXcel Therapeutics.

BTAI stock was acquired by a variety of institutional investors in the last quarter, including Driehaus Capital Management LLC, Massachusetts Financial Services Co. MA, Nuveen Asset Management LLC, Orbimed Advisors LLC, BlackRock Inc., Federated Hermes Inc., Moody Aldrich Partners LLC, and EAM Global Investors LLC. Company insiders that have bought BioXcel Therapeutics stock in the last two years include Frank Yocca, Peter Mueller, Richard I Steinhart, and Vimal Mehta. View insider buying and selling activity for BioXcel Therapeutics.

Shares of BTAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BTAI stock can currently be purchased for approximately $47.31.

BioXcel Therapeutics has a market capitalization of $956.14 million. The company earns $-32,970,000.00 in net income (profit) each year or ($2.02) on an earnings per share basis. BioXcel Therapeutics employs 18 workers across the globe.

The official website for BioXcel Therapeutics is www.bioxceltherapeutics.com.

BioXcel Therapeutics' mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The company can be reached via phone at 475-238-6837 or via email at [email protected]